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Phagocytes including neutrophil granulocytes and macrophages are important 
cells of the innate immune system whose primary function is to ingest and destroy 
microorganisms. Neutrophils help their host fight infections by phagocytosis, 
degranulation, and neutrophil extracellular traps. Neutrophils are the most com-
mon type of circulating white blood cells and the principal cell type in acute 
inflammatory reactions. A total absence of neutrophils or a significant decrease in 
their number leads to severe immunodeficiency that renders patients vulnerable to 
recurrent infections by Staphylococcus aureus and Gram-negative bacteria being the 
most life-threatening. Neutropenia may be classified as mild, moderate or severe 
in terms of numbers in the peripheral blood, and intermittent, cyclic, or chronic 
in terms of duration. Besides well-known classic severe congenital neutropenia, 
chronic neutropenia appears to be associated with an increasing number of primary 
immunodeficiency diseases (PIDs), including those of myeloid and lymphoid 
lineage. A comprehensive overview of the diverse clinical presenting symptoms, 
classification, aetiological and genetic etiologies of chronic isolated and syndromic 
neutropenia is aimed to be reviewed.
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1. Introduction
Inborn errors of immunity, traditionally called primary immunodeficiency 
diseases (PIDs) are a group of genetic defects that interfere with a component of 
the human immune system. Over the past decade, substantial knowledge has been 
gained regarding the genetic abnormalities involved in the pathogenesis of PIDs. 
More than 400 distinct disorders with 430 gene defects have been reported in the 
2019 International Union of Immunological Societies (IUIS) phenotypical classifi-
cation of human inborn errors of immunity [1]. Despite developmental changes in 
normal values for white blood cell counts during childhood and discrepancies in the 
mean value of neutrophil counts observed in people from different ethnicities, an 
absolute neutrophil count of less than 1500/μL is accepted as neutropenia. Absolute 
neutrophil count (ANC) is determined by multiplying the total leukocyte count 
by the percentage of segmented neutrophils and bands in the peripheral blood. 
Neutropenia may be defined as mild neutropenia, with an ANC of 1000–1500/μL; 
moderate neutropenia, with an ANC of 500–1000/μL; severe neutropenia, with 
an ANC <500/μL or agranulocytosis (ANC <200/μL). Neutropenia is defined to be 
chronic if it lasts longer than 3 months. Neutropenia may be chronic, intermittent, 
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or cyclic. Peripheral neutrophil granulocyte counts show sinusoidal variation with 
21 days in cyclic neutropenia.
Neutropenia is a common hematological manifestation of several PIDs with 
diverse genetic defects varying from congenital defects of phagocytes, to combined 
immunodeficiencies, and is often discovered in the course of an evaluation for acute 
infection. Congenital neutropenias associated with primary immunodeficiency 
diseases range from isolated severe congenital neutropenia to complex inherited 
disorders that comprise intellectual disabilities, organ abnormalities, facial dys-
morphism or skin hypopigmentation. In IUIS classification, congenital defects of 
phagocytes are listed in two main groups; I. Defects of phagocyte number (neutro-
penia), and II. Functional defects of phagocytes [1]. In addition to the IUIS classifi-
cation, chronic or intermittent neutropenia can be observed in other inborn errors 
of immune system, such as X-linked agammaglobulinemia, CD40L deficiency, 
reticular dysgenesis, WHIM syndrome, or in diseases of immune dysregulation. 
Defective myeloid cell differentiation, defective release of granulocytes from the 
bone marrow, enhanced apoptosis, or increased destruction of peripheral blood 
granulocytes are the main pathophysiological mechanisms underlying chronic 
severe or intermittent neutropenia in PID patients [1–3]. Primary immunodefi-
ciency disorders associated with chronic or intermittent neutropenia are listed in 
Table 1.
Neutropenia increases host susceptibility to bacterial and fungal infections, 
primarily from their endogenous flora in the gut, mouth and skin as well as from 
nosocomial organisms, and usually presents with infections of mucous membranes, 
gingiva, and skin. Staphylococcus aureus, Gram-negative bacteria, and fungi are the 
most common pathogens. The most common presenting features of neutropenia 
are fever, aphthous stomatitis, and gingivitis. Recurrent gingivitis with multiple 
dental caries may lead to teeth loss. The spectrum of infections varies from localized 
cellulitis, furunculosis, perirectal inflammation, sinusitis, and otitis media to more 
severe infections such as pneumonia, colitis, intestinal perforation with perito-
nitis, deep tissue abscess, and sepsis. Patients with severe congenital neutropenia 
develop severe bacterial infections in the first year of life. In some cases, inherited 
neutropenia may predispose to acute myeloid leukemia (AML) or myelodysplastic 
syndrome (MDS).
1.1 Primary genetic defects of severe congenital neutropenia
Severe congenital neutropenia (SCN) comprise multiple hereditary syndromes, 
with or without extrahaematopoietic manifestations. It is characterized by an 
arrest in myeloid maturation at the promyelocyte-myelocyte stage and an absence 
of mature neutrophils in the bone marrow. Regardless of the molecular etiology, 
congenital neutropenia is rare with an estimated prevalence of <1/100,000 [4–6]. 
Patients are prone to recurrent infections such as otitis, sinusitis, gingivitis, stoma-
titis, skin infections, pneumonia, deep abscesses, and septicemia beginning in their 
first months of life. Furthermore, SCN patients have an increased risk of malignant 
transformation, AML, or MDS.
Mutations in numerous genes have been identified in SCN [1, 4, 5]. The preva-
lence of some genetic subtypes of SCN is dependent on ethnicity. Autosomal 
dominant heterozygous mutations of ELANE or ELA2, encoding neutrophil 
elastase, a serine protease that is stored in the azurophilic granules, are the most 
prevalent cause of SCN in Caucasians [7–9]. ELANE mutations lead to accelerated 
apoptosis as a result of abnormal protein folding in the endoplasmic reticulum and 
altered function through mutant neutrophil elastase mislocalization. ELANE defi-


































AD, sporadic ELANE /
ELA2
Activation of the unfolded protein response (UPR), 
apoptosis of myeloid progenitor cells
Leukemia and myelodysplastic syndrome predisposition
HAX1 deficiency AR HAX1 Destabilization of mitochondrial membrane 
potential, abgrogated G-CSFR signaling, enhanced 
apoptosis of myeloid and neuronal cells




AR G6PC3 Impaired intracellular glucose homeostasis, 
dysglycosylation and UPR lead to enhanced 
apoptosis of myeloid cells
Thrombocytopenia, visible superficial veins, congenital heart 
defects, uropathy, cryptorchidism
X-linked neutropenia XL WASP Disturbed actin polymerization, altered cytoskeletal 
responses, defective mitosis and cytokinesis
Lymphopenia, leukemia predisposition
Jagunal homolog 1 
deficiency
AR JAGN1 Aberrant N-glycosylation of multiple proteins, 
elevated apoptosis
CSF3 hypo/un-responsiveness
GFI1 deficiency AD GFI1 Impaired neutrophil differentiation, lymphoid 
immunodeficiency
Monocytosis, lymphopenia
SEC61A1 deficiency AD SEC61A1 Disturbed protein translocation, and dysregulation 
of the UPR




AR CSF3R Transmembran GCSF receptor/intracellular 
signaling
CSF3 unresponsiveness









AR LYST Defective biogenesis of lysosomes, cytotoxic 
granules and melanosomes
Partial oculocutaneous albinism, recurrent infections, fever, 
hepatosplenomegaly, bleeding tendency, neurological dysfuntions, 











Inheritance Gene Pathogenic mechanism Clinical and laboratory features in addition to neutropenia
Griscelli syndrome type 
IIb
AR RAB27a Defective priming of cytotoxic granules and 
melanosomes
Recurrent infections, fever, hepatosplenomegaly, specific hair shaft 
anomaly
Cohen syndrome AR COH1, 
VPS13B
Altered vesicle sorting and transport Psychomotor retardation, microcephaly, facial dysmorphism, 
hypotonia, joint laxity, obesity, retinochoroidal dsytrophy
Hermansky-Pudlak 
syndrome
AR AP3P1 Defective endosome formation and lysosomal 
protein sorting,in immune cells
Recurrent infections, pulmonary fibrosis
VPS45 deficiency AR VPS45 Defective endosomal trafficking leads to impaired 
differentiation and motility and increased apoptosis 
of myeloid and mesenchymal cells
Myelofibrosis, nepromegaly, hepatomegaly, mental retardation
P14 deficiency AR LAMTOR2 Aberrant distribution of late endosomes, defective 
MAPK and ERK signaling, diminished phagocytosis
Growth delay, short stature, oculocutaneous hypopigmentation, 
partial albinism, coarse facial features




AR SBDS Mitotic spindle destabilization, genomic instability, 
enhanced apoptosis
Exocrine pancreas deficiency, metaphyseal dysplasia, mental 
retardation, cardiomyopathy
Dyskeratosis congenita XL DKC1 Dysfunctional telomere maintenance Skin pigmentation, nail dysplasia, oral leucoplakia, pulmonary 




Glycogen storage disease 
type 1b
AR SLC37A4 Impaired intracellular glucose homeostasis Hypoglycemia, fasting hyerlacticacidemia, hepatomegaly
Barth syndrome XL TAZ1 Mitochondrial dysfunction, destabilization of 
mitochondrial respiratory chain complexes, 






























Inheritance Gene Pathogenic mechanism Clinical and laboratory features in addition to neutropenia
Pearson syndrome Mitochondrial Deletion of 
mtDNA
Variably sized mtDNA deletion, variable 
heteroplasmy, and mosaicism lead to metabolic 
disorder/energy failure and apoptosis in affected 
tissues
Bone marrow failure, vacuoles in erythroid precursors, exocrine 





XL BTK unclear Recurrent bacterial infections, hypogammaglobulinemia, absent B 
cells
Hyper IgM syndrome AR CD40 Abrogated CD40LG:CD40-signalling, 
autoimmunity
Class-switch recombination deficiency, combined 
immunodeficiency oppurtunistic infections, biliary tract and liver 
disease, Cryptosporidium infections, intermittent neutropenia
XL CD40L
WHIM syndrome AD CXCR4 Constitutively activated CXCR4 impairs 
chemokinesis of neutrophils, dendritic cells and B 
cells from the bone marrow
Warts, hypogammaglobulinemia, immunodeficiency, 
myelokathexis
Reticular dysgenesis AR AK2 Defective mitochondrial adenine nucleotide 
homeostasis, enhanced apoptosis
Lymphopenia (T-B-NK- SCID), deafness
GATA2 deficiency AD GATA2 Complex ontogenic dysregulation of hematopoiesis 
and vascularization, reduced numbers of 
hematopoietic stem cells
Sensoryneural deafness, lymphoedema, pulmonary alveolar 
proteinosis
STK4/MST1 deficiency AR STK4 Disturbed mitochondrial membrane potential, 
enhanced apoptosis
Intermittent neutropenia, bacterial, viral (HPV, EBV, 
molluscum), candidal infections, lymphoproliferation, combined 
immunodeficiency, congenital heart defects
Cartilage-Hair 
hypoplasia
AR RMRP Defective ribosome assembly, aberrant cell cycle 
control and telomere function
Short-limbed dwarfism, metaphyseal dysostosis, sparse hair, 
autoimmunity, lymhopenia, bone marrow failure, lymphoma 
predisposition
Table 1. 
Inheritance patterns, pathogenic mechanisms and important hematological or extrahematopoietic features of primary immunodeficiency diseases associted with neutropenia.
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oscillations with the ANC ranging from normal to <200/μL with a periodicity of the 
21 days (±4 days) cycle [9]. Recessive disorders, such as HAX1, G6PC3, JAGN1 are 
usually diagnosed in consanguineous families. Mutations in TAZ (Barth syndrome) 
and WAS have X-linked inheritance [4, 5, 10, 11]. Digenic or multigenic mutations 
have been also reported in SCN patients [12]. Some mutations are linked to the 
geographic origin [10, 13–15]. Autosomal recessive (AR) HAX1 mutations account 
for about 15% of SCN patients, mostly from consanguineous Kurdish patients from 
the Middle East. AR G6PC3 mutation has a high prevalence (25%) in Israel among 
Arameans [13, 16].
Several genetic defects have been identified as being responsible for SCN and there 
is currently no clear genotype–phenotype correlation for this syndrome. Patients with 
ELANE, germline CSF3R mutations and WAS/X-linked severe congenital neutropenia 
usually present without extrahaematopoietic manifestations [10, 13, 14].
Homozygous mutations in the antiapoptotic gene HAX1, encoding ubiquitously 
expressed HCLS1-associated protein X-1 protein, are the defects identified in classic 
Kostmann syndrome [10]. HAX1 is critical for the maintenance of inner mitochon-
drial membrane potential and is an important regulator of myeloid homeostasis. 
There are 2 HAX-1 isoforms. HAX1 mutations affecting both isoforms (mainly 
p.Q190X and p.R86X) cause SCN frequently accompanied by neurological involve-
ment (mental retardation, developmental delay, and seizures). Mutations affecting 
only one isoform (mainly p.W44X in Turkish patients) lead to SCN without neuro-
logical symptoms [14].
GFI1 (Growth factor independent 1) is a zinc finger transcription factor impor-
tant in myeloid and lymphoid differentiation. Dominant-negative GFI1 mutations 
cause a severe maturation arrest of myeloid cells [4, 13].
Inactivating, X-linked mutations in WAS, the Wiscott–Aldrich syndrome gene, 
are responsible for the classical immune deficiency, microthrombocytopenia, 
autoimmunity, bleeding diathesis, and predisposition to lymphoma. Apart from 
classic Wiscott–Aldrich syndrome, XLN is a rare familial form of SCN caused by 
autosomal dominant gain-of-function mutations in WAS. WAS protein participates 
in the dynamic regulation of actin polymerization. The gain-of-function mutations 
cause an overactive protein, leading to elevated actin polymerization, defective 
cytokinesis, increased apoptosis, and neutropenia [13, 15].
Mutations in G6PC3 (glucose-6-phosphatase catalytic unit 3) were found to be a 
cause of SCN in 2009 [16]. G6PC3 is involved in the final step of the gluconeogenic 
and glycogenolytic pathway. Neutrophils of the patients have an increased sensitiv-
ity to apoptosis. Associated findings include congenital heart defects, urogenital 
abnormalities, inner ear hearing loss, and venous angiectasia [16, 17].
Homozygous mutations in protein jagunal homolog 1 (JAGN1) has been described 
as one of the causes of SCN in 2014 by Boztug et al [18]. JAGN1 deficient neutrophils 
show ultrastructural defects in the endoplasmic reticulum, absence of granules, defec-
tive N-glycosylation of multiple proteins, increased endoplasmic reticulum stress, and 
intracellular calcium activation leading to accelerated apoptosis. The phenotypic spec-
trum of JAGN1 deficiency includes short stature, scoliosis, hip dysplasia, amelogenesis 
imperfecta, facial dysmorphism, pyloric stenosis, urogenital and cardiac abnormali-
ties. Besides neutropenia, hypogammaglobulinemia, low class-switched memory B 
cells, and CD4+ T cell lymphopenia are reported in JAGN1-deficient patients. This 
form of SCN does not respond to Colony Stimulating Factor 3 (CSF3), formerly called 
granulocyte colony-stimulating factor (GCSF) treatment [18, 19].
Colony stimulating factor 3 (CSF3), the main growth factor that controls 
both the proliferation and differentiation of myeloid progenitor cells into neu-
trophils, is the primary ligand for granulocyte colony-stimulating factor receptor 
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(G-CSFR). G-CSFR is encoded by the colony-stimulating factor 3 receptor gene 
(CSF3R). Somatic CSF3R gene mutations occur on a background of inherited 
mutations affecting genes such as ELANE, HAX1, and G6PC3. Acquired point 
mutations are localized within the intracellular domain of the receptor, and 
give rise to the truncated form of the receptor. This type of receptor introduces 
a premature stop codon and hampers its ability to transduce signals required 
for neutrophil differentiation. Patients who do not respond to CSF3 should be 
checked for CSF3R mutations [3–5, 7, 20]. Despite acquired CSF3R mutations, 
congenital forms of CSF3R mutations are localized within the extracellular or, 
rarely, the transmembrane domain of the receptor [20, 21].
Recently, an autosomal dominant mutation in SEC61A1 was reported in a patient 
with SCN who was born to nonconsanguineous Belgian parents [22]. SEC61A1, 
encoding the α-subunit of the Sec61 complex controls the endoplasmic reticulum 
protein transport and passive calcium leakage. The mutation resulted in diminished 
protein expression, disturbed protein translocation, an increase in calcium leak-
age from the endoplasmic reticulum, and dysregulation of the unfolded protein 
response. The index patient presented with recurrent sinopulmonary infections, 
skin abscess, oral aphthous lesions, and enteritis, and responded well to CSF3 
treatment.
Compensatory monocytosis, hypereosinophilia, and polyclonal hypergamma-
globulinaemia appeared to be frequently associated with neutropenia and inversely 
proportional to its severity in SCN patients [13, 23].
Treatment of severe chronic neutropenia should focus on the prevention of 
infections. It includes antimicrobial prophylaxis, generally with trimethoprim-
sulfamethoxazole, and also Colony Stimulating Factor 3 (CSF3). Prior to the 
era of filgastrim/CSF3 therapy, most patients died of infectious complications 
within the first 1–2 years of life despite antibiotic prophylaxis. More than 95% of 
SCN patients respond to CSF3 treatment with an increase in the ANC, a decrease 
in infections, and a great improvement in life expectancy [24, 25]. The dose and 
frequency of injection of CSF3 vary widely. For most patients, 5–8 micrograms 
(mcg) per kilogram (kg) of body weight of CSF3 given as a daily subcutane-
ous injection is usually sufficient. SCN is a premalignant condition. Studies 
showed the cumulative incidence of malignant transformation towards AML/
MDS as about 22% after 8–15 years of CSF3 treatment [13, 25–27]. Patients who 
do not respond to filgrastim or who require high doses (>8–10 mcg/kg/day) and 
patients who develop AML or MDS should be considered for hematopoietic stem 
cell transplantation (HSCT). The strongly increased AML/MDS risk is a feature 
shared between ELANE, HAX1, and XLN SCN patients. A major risk factor for 
leukemogenesis in patients with severe congenital neutropenia is the expansion 
of hematopoietic clones with somatic (acquired) mutations in the gene encoding 
the G-CSF receptor (CSF3R). Due to the risk of developing AML or MDS, regular 
monitoring with blood counts, and yearly bone marrow aspiration and biopsy, 
including karyotyping, cytogenetic analysis, and fluorescence in situ hybridiza-
tion should be performed. The most common cytogenetic feature is monosomy 
7, which is detectable in approximately two-thirds of malignancies, but other 
recurrent cytogenetic abnormalities are also observed, such as trisomy 21 or 
trisomy 18 [23, 27].
1.2 Disorders of molecular processing
Shwachmann-Diamond syndrome and dyskeratosis congenita are in the group 




Shwachmann-Diamond syndrome is an autosomal recessive bone marrow 
failure syndrome characterized by neutropenia, exocrine pancreatic insufficiency, 
hepatic dysfunction, short stature and a wide spectrum of skeletal abnormalities. 
In addition to neutropenia, some children with SDS have defects in neutrophil 
chemotaxis or in the number and function of T, B and natural killer cells [28]. Bone 
marrow examination revealing condensed chromatin and hyposegmented neutro-
phils are in favor of Shwachman-Diamond syndrome.
1.2.2 Dyskeratosis congenita
Dyskeratosis congenita is a disorder of telomerase activity, usually presenting 
with neutropenia or pancytopenia due to bone marrow failure, cutaneous findings 
such as nail dystrophy, leukoplakia, malformed teeth, palmar hyperkeratosis, and 
hyperpigmentation of the skin [28, 29].
1.3 Disorders of metabolism
1.3.1 Glycogen storage disease type Ib
Glycogen storage disease type Ib is caused by mutations in the SLC37A4 gene, 
encoding glucose-6-phosphate translocase (G6PT). It is characterized by hypogly-
cemia, excessive glycogen accumulation in the liver and kidney, neutropenia, and 
susceptibility to bacterial infections [4, 30].
1.3.2 Barth syndrome
Barth syndrome is a rare X-linked genetic disease characterized by cardiomyopa-
thy, skeletal myopathy, growth delay, neutropenia, and increased urinary excretion 
of 3-methylglutaconic acid. Neutropenia can be constant, intermittent, or cyclic. 
Disabling mutations or deletions of TAZ gene, encoding tafazzin (a mitochon-
drial acyltransferase) cause the disorder by reducing remodeling of cardiolipin, a 
principal phospholipid of the inner mitochondrial membrane [31]. Survival is poor, 
largely depending on the severity of heart failure and the availability of a heart 
transplant.
1.3.3 Pearson syndrome
Pearson syndrome is an extremely rare mitochondrial disorder presenting with 
early-onset transfusion-dependent macrocytic sideroblastic anemia, neutropenia, 
and thrombocytopenia [32]. Additional clinical findings are failure to thrive, exo-
crine pancreatic insufficiency, and liver dysfunction. Bone marrow analyses show 
characteristic vacuolization of erythroid and myeloid precursor cells and ringed 
sideroblasts.
1.4 Vesicular trafficking disorders
Autosomal recessive vesicular trafficking disorders are caused by defects in the 
biogenesis or intracellular trafficking of lysosomes and related endosomal organ-
elles [33]. Neutropenia, low natural killer and cytotoxic T lymphocyte activities and 
abnormal platelet functions can be observed in the patients.
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1.4.1 Chediak-Higashi syndrome
Chediak-Higashi syndrome (CHS) is a rare autosomal recessive lysosomal 
disorder characterized by frequent infections, oculocutaneous albinism, bleeding 
diathesis, progressive neurologic deterioration and a high risk of developing hemo-
phagocytic lymphohistiocytosis characterized by pancytopenia, high fever, and 
lymphohistiocytic infiltration of liver, spleen, and lymph nodes [33, 34]. Treatment 
of accelerated phase is difficult with poor prognosis. Observation of giant cytoplas-
mic granulations helps dicrimination of CHS from other PIDs with partial albinism 
and neutropenia.
1.4.2 Griscelli syndrome type 2
Griscelli syndrome type 2 (GS2) is a rare, autosomal recessive immunodefi-
ciency caused by mutations in RAB27A, clinically characterized by pigmentary 
dilution of the skin and the hair and predisposition to uncontrolled T-lymphocyte 
and macrophage activation syndrome (known as hemophagocytic syndrome), 
leading to death in the absence of bone-marrow transplantation. Most patients 
also develop periods of lymphocyte proliferation and activation, leading to their 
infiltration in many organs, such as the nervous system, causing secondary neuro-
logical damage [34–36].
1.4.3 Hermansky-Pudlac syndrome type 2
Hermansky-Pudlac syndrome type 2 (HPS-2) is caused by mutations in the 
AP3B1 gene, have prominent facial features, a tendency toward bleeding, neutrope-
nia, oculocutaneous albinism and high risk for rapidly fibrosing lung disease during 
early childhood [37].
Examination of the hair shaft of patients with partial albinism can be helpful 
diagnostically, as irregular large melanin granules can be seen in Griscelli syndrome 
type 2, poorly distributed regular melanin granules in CHS, and small pigment 
clumps in Hermansky-Pudlac syndrome type 2 [34].
1.4.4 P14 deficiency
A ubiquitously expressed endosomal protein MAPBPIP or p14, encoded by the 
LAMTOR2 (Late Endosomal/Lysosomal Adaptor, MAPK and MTOR Activator 2) 
gene, is crucial for the function of neutrophils, B cells, cytotoxic T cells and melano-
cytes. Adaptor molecule p14 defects cause an immunodeficiency syndrome associ-
ated with growth delay, short stature, oculocutaneous hypopigmentation, partial 
albinism, coarse facial features, lymphoid deficiency, neutropenia, and recurrent 
bronchopulmonary infections [38].
1.4.5 Cohen syndrome
Cohen syndrome, associated with an arrest of myeloid differentiation is caused 
by an AR mutation of the vacuolar protein sorting 13 homolog B (VPS13B, also 
referred to as COH1) gene on chromosome 8q22.2. It has diverse clinical manifesta-
tions including failure to thrive, hypotonia, microcephaly, craniofacial and limb 





Vacuolar sorting protein 45 (VPS45) is a peripheral membrane protein that 
controls membrane fusion through the endosomal/lysosomal trafficking and the 
release of inflammatory mediators. Autosomal recessive inherited VPS45 deficiency 
is a severe primary immune deficiency characterized by neutropenia, myelodys-
plasia, progressive bone marrow fibrosis, impaired migration, endocytosis, and 
degranulation of neutrophils, megathrombocytopenia, increased cell apoptosis 
leading to overwhelming bacterial infections, and early death. Organomegaly, 
nephromegaly, neuromotor developmental delay, and osteosclerosis are also 
observed in VPS45 deficient patients [41–43]. Recombinant CSF3 therapy is not 
sufficient to achieve improvement in ANC counts. An early diagnosis of the condi-
tion is important as therapeutic options are currently limited to early hematopoietic 
stem cell transplantation.
1.5  Well-known primary immunodeficiency diseases associated with 
neutropenia
Primary immunodeficiency diseases are characterized by recurrent or chronic 
infections, autoimmunity, inflammation, allergy, or malignancy as a consequence 
of genetic alterations affecting the immune system. These disorders were initially 
considered to be rare, but many patients with PIDs have been recognized over the 3 
decades with the increase in awareness and availability of better diagnostic facili-
ties. The prevalence and distribution of the ten groups of inborn errors of immunity 
vary worldwide. Additionally, patients with the same disease may present a differ-
ent clinical profile and outcome. Due to the limited number of registries, incon-
sistency in diagnostic criteria, different clinical phenotypes, and lack of molecular 
diagnosis, the global perspective of these diseases remains unclear. Reports from 
several PID registries in different countries show a prevalence of 1:8500 to 1:100000 
for symptomatic patients [44–46]. Predominantly B-cell deficiencies encompass 
the main category of PIDs. Although the exact data about the frequency is lack-
ing, a great number of immune deficiencies are known to be associated with mild 
or severe neutropenia as a result of close interactions both in their ontogeny and 
during their functional life of myeloid and lymphoid cells. Most of such cases of 
neutropenia are observed at diagnosis and may recover once appropriate therapy is 
administered, such as parenteral immunoglobulin replacement in B cell deficiency.
1.5.1 Bruton’s disease
X-linked agammaglobulinemia (XLA) is a rare primary immune deficiency 
characterized by the absence of circulating B cells with a severe reduction in all 
serum immunoglobulin levels due to mutations in the BTK gene. B cells show a 
developmental arrest in the bone marrow at the pro-B to the pre-B stage in the 
presence of mutations in BTK. Most XLA patients present with recurrent bacte-
rial infections such as otitis, sinusitis, and sinopulmonary infections, developing 
after 7 to 9 months of age when transplacental maternal immunoglobulin G (IgG) 
levels decrease below protective levels. Streptococcus pneumoniae and Haemophilus 
influenzae are the most common responsible encapsulated pathogens. Patients are 
specifically susceptible to Enterovirus family, and mostly to poliovirus, coxsackie 
virus (hand, foot, and mouth disease), and Echoviruses. These may cause severe 
central nervous system conditions as chronic encephalitis, meningitis, and death. 
Prevalence is approximately 1 per 10,000 [47, 48]. Almost 30% of XLA patients are 
reported to have profound neutropenia at the time of diagnosis and the resolving 
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of neutropenia after initiation of regular IVIG replacement therapy [49–51]. The 
direct involvement of BTK in neutrophil development is not clear.
1.5.2 CD40LG deficiency (Hyper IgM syndrome type I)
The Hyper IgM (HIGM) syndromes are a group of rare genetic disorders 
leading to loss of T cell-driven immunoglobulin class switch recombination (CSR) 
and/or defective somatic hypermutation (SHM) with elevated or normal serum 
IgM and decreased IgG, IgA, and IgE. The most common causes are mutations in 
the CD40 Ligand (CD154) (CD40LG) gene leading to X-linked HIGM (XHIGM) 
in males. Interaction between CD40L expressed by the Thelper subset and its recep-
tor CD40 on B cells induces B cell proliferation, CSR, and SHM. Patients with 
HIGM are highly susceptible to recurrent sinopulmonary infections, Pneumocystis 
jiroveci pneumonia, and chronic diarrhea due to Cryptosporidium infection that 
may lead to sclerosing cholangitis, hepatitis, and liver cirrhosis [52–55]. About 
50% of XHIGM patients have chronic, cyclic or intermittent neutropenia, as a 
consequence of chronic infection or autoimmunity. Studies also revealed multiple 
functions of the CD40/CD40L interactions on stromal cells by enhancing the 
expression of granulopoiesis growth factors [56]. Decreased interaction between T 
cells and bone marrow stromal cells, resulting in reduced production of G-CSF is 
one of the mechanisms of neutropenia in XHIGM patients.
1.5.3 Severe combined immunodeficiency
Severe combined immunodeficiency (SCID) syndromes are characterized by 
a block in T lymphocyte differentiation that is variably associated with abnormal 
development of other lymphocyte lineages (B and/or natural killer [NK] cells), 
leading to death early in life unless treated urgently by hematopoietic stem cell 
transplantation. The overall frequency is estimated to 1 in 75 000–100 000 births 
[44, 57]. Reticular dysgenesis, caused by a mutation in the adenylate kinase 2 (AK2) 
gene is an autosomal recessive disease with granulocytopenia as well as pancyto-
penia, lack of innate and adaptive immune responses, and sensorineural deafness 
[1, 57]. Mitochondrial adenylate kinase (AK) regulates levels of adenosine diphos-
phate. AK2 deficiency results in increased apoptosis of myeloid and lymphoid 
precursors. This form is one of the rarest and most severe types of SCID. Severe 
infections occur earlier than in other forms of SCID due to profound neutropenia, 
in addition to markedly decreased T and NK cells.
1.5.4 Wiskott Aldrich syndrome
Wiskott Aldrich syndrome (WAS) results from a loss of function mutation in 
Wiskott-Aldrich syndrome protein (WASP) and presents with recurrent infec-
tions, eczema and microthrombocytopaenia [58]. In its classical form, significant 
combined immune deficiency, autoimmune complications, and risk of hematologi-
cal malignancy necessitate early correction with stem cell transplantation or gene 
therapy. In Wiskott-Aldrich syndrome, neutropenia usually accompanies frequent 
autoimmune disorders. It is different from the milder form, X-linked thrombocyto-
penia (XLT) that is caused by the activating WASP mutations.
1.5.5 WHIM syndrome
WHIM syndrome (WHIM) is an autosomal dominant congenital immune 
deficiency with susceptibility to human papillomavirus infection-induced warts, B 
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cell lymphopenia, hypogammaglobulinema, bone marrow myelokathexis (increase 
in the granulocyte pool, with hyper mature dystrophic neutrophils), and neutrope-
nia [59]. Gain-of-function mutations in the G protein-coupled chemokine receptor 
CXCR4 are causal in this disease. Mutations in this protein lead to increased respon-
siveness to its chemokine ligand CXCL12 and retention of neutrophils in the bone 
marrow. Intravenous immunoglobulin (IVIg) and CSF3 have been documented 
to prevent infections in patients with hypogammaglobulinemia and neutropenia, 
respectively. Granulocyte colony-stimulating factor can increase neutrophil counts 
but does not affect cytopenias. CXCR4 antagonist plerixafor has been used to 
increase absolute lymphocyte, monocyte, and neutrophil counts in the peripheral 
blood in a dose-dependent manner, correct neutropenia, and other cytopenias in 
WHIM syndrome [60, 61].
1.5.6 Cartilage-hair hypoplasia
Cartilage-hair hypoplasia is a rare form of skeletal dysplasia, but also a syn-
dromic primary immunodeficiency disorder due to a mutation in the RNase 
MRP RNA gene (RMRP), a non-coding RNA gene. The main clinical features are 
chondrodysplasia, short-limbed short stature, sparse and fine hair, Hirschsprung 
disease, macrocytic anemia, defective T cell-mediated immunity and predisposition 
to severe infections and cancer [62].
1.5.7 STK4/MST1 deficiency
Biallelic mutations in STK4, encoding MST1 have been identified in patients 
with CD4 lymphopenia accompanying multiple bacterial and viral infections, 
EBV-related lymphoproliferative disorder and mucocutaneous candidiasis [63–65]. 
MST1 deficiency has overlapping features with other PIDs involving defects in 
actin cytoskeletal reorganization, such as DOCK8 deficiency and Wiskott-Aldrich 
Syndrome. Hypergammaglobulinemia, progressive loss of naive T cells, reduced in 
vitro T-cell proliferation and defective in LFA-1-mediated adhesion and chemotaxis 
are the immunological disturbances identified in these patients. Clinically, these 
disorders and MST1 deficiency may behave very similarly. A thorough diagnostic 
workup including molecular genetic testing is advised to inform decision-making 
around stem cell transplantation, which will often be required.
1.5.8 GATA2 deficiency
GATA2 is a transcription factor required for stem cell homeostasis. Clinical 
presentation of GATA2 deficiency varies from typical Emberger syndrome (deaf-
ness and lymphoedema), MonoMac syndrome (susceptibility to mycobacteria, 
myelodysplasia, cytogenetic abnormalities, myeloid leukemias, pulmonary alveolar 
proteinosis) [66]. A significant proportion of patients have monocytopenia and 
macrocytosis in addition to mild neutropenia.
2. Diagnostic work-up in chronic neutropenia
Children with a history of recurrent or unusual infections present a diagnostic 
challenge. A high index of suspicion could lead to an early diagnosis and treatment 
of underlying immune deficiency disease. Several points should be taken into 
consideration in the examination of the patient. These are;
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A. Age at the first detection of neutropenia;
B. The indication that required performing a complete blood cell count (CBC) 
(mild infection/fever, severe infection, fungal infection, aphthous, gingivitis 
stomatitis, diarrhea, developmental delay);
C. A family history of neutropenia, consanguinity, pregnancy losses, or infec-
tious deaths, and geographic origin;
D. The presence of any severe infections, bacterial or fungal;
E. A physical examination that focuses on the oral cavity (ulceration, gingivitis 
or stomatitis), skin, lungs, and perirectal area for infection is important. 
Lymphadenopathy and hepatosplenomegaly must be determined.
F. The presence of any congenital malformation and/or any organ dysfunction;
G. The complete blood count with differential, performed at the time of diagnosis 
(including the ANC, absolute eosinophil count, absolute monocyte count, 
absolute lymphocyte count, hemoglobin levels, and platelet levels).
H. Some specific cytological abnormalities observed on the blood, such as large 
granular lymphocytes, suggestive of Chediak-Higashi syndrome.
The initial workup may also reveal a particular etiology, such as viral infections. 
After this screening evaluation, bone marrow aspiration, immunological tests (e.g., 
immunoglobulin G, A, M, E levels, T and B immunophenotype), pancreas markers 
(serum trypsinogen, fecal elastase), and auto-antibodies against neutrophils may 
help to determine the diagnosis. The diagnoses according to the system involvement 
are depicted in Figure 1.
Figure 1. 
Differential diagnosis of chronic neutropenia according to system involvements.
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Targeted next-generation sequencing panels on the initial genetic investigations, 
followed-by whole-exome sequencing appears to be the most efficient strategy to 
identify the molecular etiology. In addition, the search for pathogenic copy-number 
variants or for regions of homozygosity in the case of consanguineous individuals 
should be considered. Mutations in some genes such as CSF3R and GATA2 can be 
either germline or somatic. As hematopoietic cells may acquire somatic mutations, 
non-hematopoietic tissue may be tested to distinguish germline versus somatic 
mutations. Buccal swabs or saliva samples may be contaminated by hematopoietic 
cells. Therefore, the germline status of a mutation should therefore be confirmed 
by analyzing DNA extracted from non-hematopoietic tissue, such as nails, hair 
follicles, or fibroblasts.
3. Treatment and follow-up
Treatment of severe chronic neutropenia in PIDs should focus on the prevention 
of infections, the management of associated organ dysfunction, and the preven-
tion of leukemic transformation. The management of neutropenia will require a 
flexible, empiric, and patient-centered approach based on the use of cytokines 
and HSCT with consideration of antibiotic prophylaxis. Although many different 
genetic mutations may cause neutropenia, the clinical picture is similar. Most SCN 
patients find great benefit from subcutaneous CSF3 administration, which causes 
a significant decrease in the frequency of severe bacterial infections and increases 
the quality of life. The starting dose is 5 mcg/kg with dose modification according to 
the patient’s absolute neutrophil count and the rate of infections. It should be kept 
in mind that neutropenia in JAGN1 and VPS45 deficiencies do not respond to CSF3. 
Patients who do not respond to CSF3 or who require high doses (>8–10 mcg/kg/day) 
and patients who develop AML or MDS should be treated by HSCT.
The treatment of neutropenia should be decided on a patient basis for the other 
disease groups. For example, patients with Shwachmann-Diamond syndrome 
require transfusions, pancreatic enzymes, antibiotics, and CSF3. The only definitive 
therapy for marrow failure is HSCT. Neutropenia, which is frequently detected at 
the time of diagnosis in XLA (Bruton agammaglobulinemia) patients, improves 
with regular IVIG replacement. XHIGM (CD40 Ligand deficiency) patients can 
be cured by HSCT. Future treatment strategies including gene therapy or novel 
genome editing technologies using CRISPR/Cas9 or TALEN systems will permit the 
correction of monogenic neutropenia disorders.
The rate of hematological malignancy in many of the inherited neutropenia 
disorders, regardless of genetic subtype, is far higher than that observed in the 
general population. The rate of transformation is not precisely documented, but 
the leukemic transformation has been reported in patients with WAS, HAX1, 
G6PC3, SLC37A4 or acquired CSF3R gene mutations, whereas no transformation 
has been observed in patients with VPS13B or CXCR4 mutations so far [25, 27]. 
Leukaemogenesis in CN is a multi-step process. In addition to germline mutations, 
several genetic mutations may occur in myeloid cells. Annual bone marrow exami-
nation should be performed to rule out malignant haemopathies, and determine 
cellularity, assess myeloid maturation, and detect some features that are typical of a 
precise etiology in the case of chronic neutropenia.
Blood neutrophils and monocytes are the cells both produced in the bone 
marrow, circulate in the blood, and are recruited to sites of inflammation. 
Compensatory monocytosis help SCN patients overcome infections. Although both 
are actively phagocytic, they differ in significant ways. The neutrophil response 
is more rapid and the lifespan of these cells is short, whereas monocytes become 
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macrophages in the tissues, can live for long periods, and maintain tissue integ-
rity by eliminating/repairing damaged cells. Over the recent years, an increasing 
amount of knowledge has been gained in the field of phagocytic cell subpopulations 
[67, 68]. In addition to their protective role against invading pathogens, the field 
has highlighted roles for inflammatory conditions including sterile injury, tumor 
development, atherosclerosis, and autoimmunity. With regard to their high plastic-
ity, neutrophils and macrophages are shown to acquire an anti-tumorigenic N1/
M1 or a pro-tumorigenic N2/M2 phenotype, respectively. The impact of M1 macro-
phages which have overlapping features with N1 subsets of neutrophils need further 
investigation in PIDs.
4. Conclusion
Neutropenia is a common hematologic manifestation of a wide range of diseases. 
Paying careful attention to associated features of a patient provides valuable clues 
leading to a narrow spectrum of differential diagnosis. Genetic investigation may be 
helpful in making a definitive diagnosis. This is of utmost importance since timely 
diagnosis helps the patient benefit from available therapeutic modalities such as 
HSCT and CSF3 administration.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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